Short communication: The cost-effectiveness of cutaneous leishmaniasis patient management during an epidemic in Chaparral, Colombia in 2004.
Vega, Juan Carlos;
Sanchez, Boris Fernando;
Montero, Luz Mery;
Montaña, Rafael;
Del Pilar Mahecha, Mercedes;
Dueñes, Bladimir;
Baron, Angela Rocío;
Reithinger, Richard;
(2007)
Short communication: The cost-effectiveness of cutaneous leishmaniasis patient management during an epidemic in Chaparral, Colombia in 2004.
Tropical medicine & international health, 12 (12).
pp. 1540-1544.
ISSN 1360-2276
DOI: https://doi.org/10.1111/j.1365-3156.2007.01962.x
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
We calculated ranges for the cost per disability adjusted life year (DALY) averted for cutaneous leishmaniasis (CL) treatment during an ongoing epidemic of CL in Chaparral, Colombia. Using operational clinical and cost data, we calculated that the cost of treating leishmaniasis patients with standard pentavalent antimony was US$345 (95% CI 277-488) per patient treated and cured. The cost per DALY averted per patient cured with antimony was estimated to be approximately US$15 000 (95% CI 12 226-21 532).
